Company: AZN
Filing Date: 2025-09-29
Form Type: 6-K
Source: 0001104659-25-094039
Chunk: 4

Company: ASTRAZENECA PLC
Filing Date: 2025-09-29
Form: 6-K
Chunk 4
---
 or launch of new medicines;

2.

the risk of failure to meet regulatory or ethical requirements for medicine development or approval;

3.

the risk of failures or delays in the quality or execution of the Group’s commercial strategies;

4.

the risk of pricing, affordability, access and competitive pressures;

5.

the risk of failure to maintain supply of compliant, quality medicines;

6.

the risk of illegal trade in the Group’s medicines;

7.

the impact of reliance on third-party goods and services;

8.

the risk of failure in information technology or cybersecurity;

9.

the risk of failure of critical processes;

10.

the risk of failure to collect and manage data and artificial intelligence in line with legal and regulatory requirements and strategic objectives;

11.

the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce;

12.

the risk of failure to meet our sustainability targets, regulatory requirements and stakeholder expectations with respect to the environment;

<div align='center'>3</div>

TABLE OF CONTENTS

13.

the risk of the safety and efficacy of marketed medicines being questioned;

14.

the risk of adverse outcome of litigation and/or governmental investigations;

15.

intellectual property risks related to the Group’s products;

16.

the risk of failure to achieve strategic plans or meet targets or expectations;

17.

the risk of geopolitical and/or macroeconomic volatility disrupting the operation of our global business;

18.

the risk of failure in internal control, financial reporting or the occurrence of fraud; and

19.

the risk of unexpected deterioration in the Group’s financial position.

#### 4.

#### No profit forecast
Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.

<div align='center'>4</div>

TABLE OF CONTENTS

### ACTION TO BE TAKEN

#### 1.

#### Online platform
The Board strongly encourages all Shareholders (including holders of AstraZeneca Shares in a nominee account or brokerage account or through the CSN Facility) to participate in the General Meeting via the online platform, as the content and presentation will be optimised for that format. Shareholders can attend from any physical location using a personal device via the online platform, which can be found at: https://meetings.lumiconnect.com/100-392-363-424.

Further details, including joining instructions, are included in the Notes to the Notice of General Meeting in Part VII ( Notice of General Meeting ) of this document or, for holders of AstraZeneca ADSs